KRAS and small cell lung carcinoma: Furthermore, activating alterations in EGFR and KRAS, which are highly prevalent in LUAD (Cancer Genome Atlas Research Network, 2014), are rarely identified in SCLC (Peifer et al., 2012; George et al., 2015) (Summarized in Figure 1a).